Glenmark plans to launch phase 1 trial in solid tumors for GBR 1342
Glenmark Pharmaceuticals announced the decision to launch a Phase 1 trial in solid tumors for its CD38xCD3 bispecific antibody GBR 1342. The decision is driven by recent findings…
Read More...
Read More...
